The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using chemo- and radio-therapy modestly increases the overall survival of patients; however, recurrence is inevitable, due to treatment resistance and lack of response to targeted therapies. GBM therapy resistance has been attributed to several extrinsic and intrinsic factors which affect the dynamics of tumor evolution and physiology thus creating clinical challenges. Tumor-intrinsic factors such as tumor heterogeneity, hypermutation, altered metabolomics and oncologically activated alternative splicing pathways change the tumor landscape to facilitate therapy failure and tumor progression. Moreover, tumor-extrinsic factors such as hypoxia and an immune-suppressive tumor microenvironment (TME) are the chief causes of immunotherapy failure in GBM. Amid the success of immunotherapy in other cancers, GBM has occurred as a model of resistance, thus focusing current efforts on not only alleviating the immunotolerance but also evading the escape mechanisms of tumor cells to therapy, caused by inter- and intra-tumoral heterogeneity. Here we review the various mechanisms of therapy resistance in GBM, caused by the continuously evolving tumor dynamics as well as the complex TME, which cumulatively contribute to GBM malignancy and therapy failure; in an attempt to understand and identify effective therapies for recurrent GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most tumors are poorly vascularized and hypoxic, which advances cancer progression and chemoresistance [70, 71].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · cited 9×
“Increasing mitochondrial ROS (mROS) has also been investigated to sensitize cells to RT. Post-radiation, the Hypoxia Inducible Factor 1α (HIF1α) target gene pyruvate dehydrogenase kinase (PDK) has been shown to be upregulated.”
BackgroundInfluentialSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Next, earlier studies have shown that TMZ is a direct cause of hypermutation in recurrent gliomas as seen by the accumulation of a TMZ-specific mutational signature in these tumors [39,62].”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668 · cited 1×
“Gliomas with methylated MGMT promoters are more sensitive to TMZ‐in‐ duced cytotoxicity with a longer median overall survival, as compared to patients whose tumors have unmethylated MGMT promoters [5,6].”
BackgroundVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 2×
“TAMs are the dominant infiltrating immune population in glioma constituting around 30–40% of the total tumor volume [25,132,138].”
BackgroundSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 1×
“The GBM TME attracts TAMs to the tumor and polarizes them to an anti-inflammatory or pro-tumorigenic ‘M2′-like state, thus current studies are aimed at inhibiting their recruitment or survival in the TME, allowing for their functional re-education to an anti-tumor ‘M1′-like state, or targeting the tumor using monoclon…”
Background
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“However, most tumors are poorly vascularized and hypoxic, which advances cancer progression and chemoresistance [70, 71].”
BackgroundSelf-citationGlioma: molecular signature and crossroads with tumor microenvironment
Barthel, L., Hadamitzky, M., Dammann, P., Schedlowski, M., Sure, U., Thakur, B. K., & Hetze, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09997-9 · Cited by 211
The tumour microenvironment, treatment resistance and recurrence in glioblastoma
White, J., White, M. P. J., Wickremesekera, A., Peng, L., & Gray, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05301-9 · Cited by 168
“5) [28, 128].”
BackgroundInfluentialCheng, G., Kwong, C. H. T., Wang, Q., Kam, H., Xie, B., Lee, S. M., Chen, G., & Wang, R. (2023) · ACS Nano · doi:10.1021/acsnano.3c00041 · Cited by 157
Molecular Mechanisms of Drug Resistance in Glioblastoma
Dymova, M. A., Kuligina, E. V., & Richter, V. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126385 · Cited by 152
“If the BBB is disrupted by tumor proliferation or inflammation, then the tumor can be infiltrated by immunosuppressive immune cells [67].”
BackgroundWu, H., Guo, C., Wang, C., Xu, J., Zheng, S., Duan, J., Li, Y., Bai, H., Xu, Q., Ning, F., et al. (2023) · Cancer Science · doi:10.1111/cas.15773 · Cited by 116
Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets
Erices, J. I., Bizama, C., Niechi, I., Uribe, D., Rosales, A., Fabres, K., Navarro, G., Torres, Á., Martín, R. S., Roa, J. C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087047 · Cited by 123
Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance
Eckerdt, F., & Platanias, L. C. (2023) · Cancers · doi:10.3390/cancers15133458 · Cited by 110
Habashy, K. J., Mansour, R., Moussalem, C., Sawaya, R., & Massaad, M. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01864-w · Cited by 95
“TMZ, the most commonly used chemotherapeutic agent for the treatment of GBM, is a potent inhibitor of lymphocyte proliferation [185].”
BackgroundInfluentialNew Directions in the Therapy of Glioblastoma
Szklener, K., Mazurek, M., Wieteska, M., Wacławska, M., Bilski, M., & Mańdziuk, S. (2022) · Cancers · doi:10.3390/cancers14215377 · Cited by 90
“However, in the case of glioblastoma, the phenomenon of drug resistance is also a key problem [26].”
BackgroundZhao, C., Zhu, X., Tan, J., Mei, C., Cai, X., & Kong, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116113 · Cited by 92
The influence of the blood–brain barrier in the treatment of brain tumours
Rathi, S., Griffith, J. I., Zhang, W., Zhang, W., Oh, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13440 · Cited by 70
Hypoxia, a key factor in the immune microenvironment
Hu, J., Li, X., Yang, L., & Li, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113068 · Cited by 68
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors
Kim, H., Lim, K. Y., Park, J. W., Kang, J., Won, J., Lee, K., Shim, Y., Park, C., Kim, S., Choi, S. H., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00694-3 · Cited by 73
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma
Duraj, T., Kalamian, M., Zuccoli, G., Maroon, J. C., D’Agostino, D. P., Scheck, A. C., Poff, A. M., Winter, S. F., Hu, J. L., Klement, R. J., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03775-4 · Cited by 72
Wach, J., Vychopen, M., Kühnapfel, A., Seidel, C., & Güresir, E. (2023) · Cancers · doi:10.3390/cancers15061772 · Cited by 53
“, hypoxia and immuno-suppressive tumor microenvironments) mechanisms developing resistance to therapies [16].”
BackgroundBRD4: New hope in the battle against glioblastoma
Duan, W., Yu, M., & Chen, J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106767 · Cited by 51
Zhou, J., Li, L., Jia, M., Liao, Q., Peng, G., Luo, G., & Zhou, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.5511 · Cited by 45
Lai, Y., Lu, X., Liao, Y., Ouyang, P., Wang, H., Zhang, X., Huang, G., Qi, S., & Li, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.05.025 · Cited by 43
Kao, T., Lin, C.-L., Yang, W., Li, H., & Hsu, T. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01881-5 · Cited by 40
“Resistance mechanisms in GBM are complex and multifactorial but can be broadly classified into intrinsic and extrinsic factors [4].”
BackgroundHypoxia effects on glioblastoma progression through YAP/TAZ pathway regulation
Castillo, C., Grieco, M., D’Amone, S., Lolli, M. G., Ursini, O., & Cortese, B. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216792 · Cited by 38
The Role of Non-Coding RNAs in Glioma
Goenka, A., Tiek, D. M., Song, X., Iglesia, R. P., Lu, M., Hu, B., & Cheng, S. (2022) · Biomedicines · doi:10.3390/biomedicines10082031 · Cited by 39
“of action can help to build novel treatments to overcome the therapy resistance and tumor recurrence in glioma [18].”
BackgroundSelf-citationUnderstanding Neovascularization in Glioblastoma: Insights from the Current Literature
Ballato, M., Germanà, E., Ricciardi, G., Giordano, W. G., Tralongo, P., Buccarelli, M., Castellani, G., Ricci‐Vitiani, L., D’Alessandris, Q. G., Giuffrè, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062763 · Cited by 37
“Specifically, the standard of care involves an aggressive, multimodal, tripartite strategy: safe surgical debulking, radiotherapy, and adjuvant chemotherapy with the alkylating drug temozolomide (TMZ) [35–37].”
Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., & Shen, J. Q. (2025) · Polymers · doi:10.3390/polym17081010 · Cited by 36
Kim, S., Lim, E., Yoo, K.-C., Zhao, Y., Kang, J.-H., Lim, E., Shin, I., Kang, S., Lim, H. W., & Lee, S. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.997 · Cited by 36
Liang, R., Wu, C., Liu, S., & Zhao, W. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2075986 · Cited by 31
“In addition, immune suppressive microenvironment and low immunogenicity have led to immunotherapy resistance in glioblastoma treatment thus posing this approach less effective for glioblastoma therapy (Goenka et al., 2021).”
BackgroundLi, H., Feng, Y., Lin, C.-L., & Hsu, T. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.101836 · Cited by 35
Modern approaches to glioblastoma therapy
Kuznetsova, N. S., Гурова, С. В., Гончарова, А. С., Заикина, Е. В., Gusareva, M. A., & Сергеевич, З. М. (2023) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2023-4-1-6 · Cited by 26
Zhou, R., Zhao, D., Beeraka, N. M., Wang, X., Lu, P., Song, R., Chen, K., & Liu, J. (2022) · Metabolites · doi:10.3390/metabo12100943 · Cited by 32
Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies
Attia, N., Mashal, M., Pemminati, S., Omole, A. E., Edmondson, C. K., Jones, W., Priyadarshini, P., Mughal, T., Aziz, P., Zenick, B., et al. (2021) · Cells · doi:10.3390/cells11010116 · Cited by 26
“Despite the great promise immunotherapy has in cases of GB, the disease is quite notorious for its high recurrence rate [48].”
BackgroundWarrier, N. M., Krishnan, R. K., Prabhu, V., Hariharapura, R. C., Agarwal, P., & Kumar, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147604 · Cited by 26
Nasir, S., Nazir, S., Hanif, R., & Javed, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020687 · Cited by 30
“The recurrence of tumors and acquisition of resistance by GBM tumor cells is yet an unsolved problem [30].”
BackgroundHuang, M., Xu, S., Li, Y., Li, S., Zhan, X., Qin, C., Su, J., Zhao, Z., He, Y., Qin, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202205525 · Cited by 30
Hsu, J. B., Lee, T.-Y., Cheng, S., Lee, G. A., Chen, Y.-C., Le, N. Q. K., Huang, S., Kuo, D.-P., Li, Y.-T., Chang, T., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111047 · Cited by 29
Self-citationImproving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge, M., Zhu, Y., Wei, M., Piao, H., & He, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188996 · Cited by 27
Wang, Y., Gao, G., Wei, X., Zhang, Y., & Yu, J. L. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s405450 · Cited by 25
“Temozolomide (TMZ)-based chemotherapies are the standard treatment options for GBM;(3) however, GBM tumors inevitably become resistant to TMZ and patients have poor prognosis, due to the molecular heterogeneity, hyperactivation of pro-survival pathways, rapid growth rate, and immunosuppression of GBM tumors.(4) Aberra…”
BackgroundPlatelet-derived growth factor signalling in neurovascular function and disease
Li, S. Y., Johnson, R. H., Smyth, L. C. D., & Dragunow, M. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106187 · Cited by 24
Giammello, F., Biella, C., Priori, E. C., Filippo, M. A. D. S., Leone, R., D’Ambrosio, F., Paterno', M., Cassioli, G., Minetti, A., Macchi, F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01819-z · Cited by 23
“The poor prognosis of GBM arises not only from its high rate of aggressiveness and brain invasion but also from therapy resistance and tumor recurrence [3].”
BackgroundTwo Faces of Glutaminase GLS2 in Carcinogenesis
Buczkowska, J., & Szeliga, M. (2023) · Cancers · doi:10.3390/cancers15235566 · Cited by 26
“Inter-and intra-tumoral molecular, cellular, and metabolic heterogeneity significantly contributes to therapy failure in glioblastoma [116].”
BackgroundTargeted delivery of nanomedicines to glioblastoma: Overcoming the clinical barrier
Nayak, A., Warrier, N. M., Raman, R., Prabhu, V., & Kumar, P. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105980 · Cited by 24
Drug resistance in glioblastoma: Challenges, mechanisms and therapeutic strategies (Review)
Durga, Y., & Pusapati, R. V. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2913 · Cited by 36
“…heterogeneity, discussed in the previous sections, contributes to immunotherapy resistance in GBM at both the molecular and cellular levels, allowing a range of subclonal populations with distinct genetic muta‑ tions and developmental states to coexist and evolve within the same tumor (43,164).”
Gangadaran, P., Onkar, A., Rajendran, R. L., Goenka, A., Oh, J. M., Khan, F., Nagarajan, A. K., Muthu, S., Krishnan, A., Hong, C. M., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00735-9 · Cited by 22
Self-citationÇağlar, H. O., & Düzgün, Z. (2022) · Gene · doi:10.1016/j.gene.2022.146895 · Cited by 19
Spatial heterogeneity in glioblastoma: Decoding the role of perfusion
Saha, S., Bhat, A., Kukal, S., Phalak, M., & Kumar, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189383 · Cited by 19
Díaz‐Flores, L., Gutiérrez, R., González‐Gómez, M., García, M.-D.-P., Díaz-Flores, L., González-Marrero, I., Ávila, J., & Martı́n-Vasallo, P. (2021) · Cells · doi:10.3390/cells10102625 · Cited by 17
Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology
Chen, S., Jiang, J., Shen, A., Miao, Y., Cao, Y., Zhang, Y., Cong, P., & Gao, P. (2022) · Metabolites · doi:10.3390/metabo12100918 · Cited by 18
The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
Neth, B. J., Webb, M., Parney, I. F., & Sener, U. T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041134 · Cited by 25
Targeting brain tumours with precision: advances in magnetic nanoparticle therapy
Preetam, S., Rabbee, M. F., Mishra, R., Thapliyal, S., Deshwal, R. K., Rustagi, S., Dashmana, A., Govindarajan, R. K., & Malik, S. (2025) · Nanoscale Advances · doi:10.1039/d5na01046b · Cited by 17
“9,10 As a result, there is an urgent need for innovative therapeutic strategies that can e ff ectively target these malignancies.”
Warrier, N. M., Agarwal, P., & Kumar, P. (2021) · Cells · doi:10.3390/cells10102765 · Cited by 16
Ahmad, N., Chen, L., Yuan, Z., Ma, X., Yang, X., Wang, Y., Zhao, Y., Jin, H., Khaidamah, N., Wang, J., et al. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00431 · Cited by 16
“Even with intensive therapeutic interventions including surgery, radiation, and chemotherapy, GBM patient survival had not signi fi cantly improved [31], and the majority of GBM patients underwent recurrence, which might be potentially fatal [32].”
Can ECIS Biosensor Technology Be Used to Measure the Cellular Responses of Glioblastoma Stem Cells?
Robilliard, L. D., Yu, J. J., Jun, S.-M., Anchan, A., Finlay, G. J., Angel, C. E., & Graham, E. S. (2021) · Biosensors · doi:10.3390/bios11120498 · Cited by 15
“Glioblastoma is one of the most devastating forms of brain cancer, owing to the lack of treatment options, complexity of the tumour locations restricting surgical options, and the dismal survival statistics [1].”
BackgroundA novel hypoxia-driven gene signature that can predict the prognosis and drug resistance of gliomas
Ren, P., Wang, J., Zeng, Z., Li, N., Chen, H., Peng, X.-G., BHAWAL, U. K., & Guo, W.-Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.976356 · Cited by 16
Broggi, G., Piombino, E., Altieri, R., Romano, C., Certo, F., Barbagallo, G. M. V., Vigneri, P. G., Condorelli, D., Colarossi, L., Colarossi, C., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.823015 · Cited by 16
Wang, S., Li, X., Hu, Y., Wang, L., Lv, G., Feng, Y., Sun, Z., Cao, Z., Liu, Y., & Wang, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116066 · Cited by 14
Barriers to overcoming immunotherapy resistance in glioblastoma
Gillette, J. S., Wang, E. J., Dowd, R. S., & Toms, S. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1175507 · Cited by 14
“Glioblastoma inter- and intra-tumoral heterogeneity (ITH) is one of the primary intrinsic mechanisms explaining therapy resistance in GBM, ultimately resulting in hypermutation that creates clinical barriers (41).”
BackgroundSiderol Inhibits Proliferation of Glioblastoma Cells and Acts Synergistically with Temozolomide
Giannakopoulou, M., Dimitriadis, K., Koromili, M., Zoi, V., Vartholomatos, E., Galani, V., Kyritsis, A. P., Alexiou, G. Α., & Lazari, D. M. (2022) · Biomedicines · doi:10.3390/biomedicines10123216 · Cited by 12
“In addition, both radio and chemo resistance constitute inhibitory factors for the successful treatment of GBM [19].”
BackgroundTargeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy
Dowdell, A., Marsland, M., Faulkner, S., Gedye, C. A., Lynam, J. F., Griffin, C. P., Marsland, J., Jiang, C. C., & Hondermarck, H. (2023) · FASEB BioAdvances · doi:10.1096/fba.2022-00141 · Cited by 15
A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion
Rybin, M. J., Laverde-Paz, M. J., Suter, R. K., Affer, M., Ayad, N. G., Feng, Y., & Zeier, Z. R. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128614 · Cited by 12
Blanchard, R., & Adjei, I. M. (2023) · RSC Advances · doi:10.1039/d3ra01153d · Cited by 11
Zheng, C., Wang, P., Zhang, D., Fang, Z., Feng, Y., Chen, J., Chen, J., Fu, Y., Yang, B., Yu, S., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.07.015 · Cited by 30
“Retaining tumor cells, autologous tumor-related immune cells, and stromal cells are crucial for drug screening and reflecting the in vivo situation [29].”
Photoresponsive Inorganic Nanomaterials in Oncology
Barbero, F., Gul, S., Perrone, G., & Fenoglio, I. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231192850 · Cited by 14
“The ability of malignant cells to adapt and evolve in response to therapy makes it difficult to effectively treat and cure cancer.(4) Along with surgery and radiotherapy, chemotherapy is one of the foundations of cancer treatment today.”
BackgroundSignificance of circulating tumor cells detection in tumor diagnosis and monitoring
Liu, Y., Zhao, R., Xie, Z., Pang, Z., Chen, S., Xu, Q., & Zhang, Z. (2023) · BMC Cancer · doi:10.1186/s12885-023-11696-3 · Cited by 14
“However, tumor recurrence is often an unavoidable fact [1], so cancer patients often undergo regular check-ups [2, 3].”
Iglesia, R. P., Prado, M. B., Alves, R. N., Melo-Escobar, M. I., Fernandes, C. F. D. L., Fortes, A. C. D. S., Souza, M. C. D. S., Boccacino, J. M., Cangiano, G., Soares, S. R., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.907423 · Cited by 11
Self-citationMarshall, K. L., Velayutham, M., Khramtsov, V. V., Mizener, A. D., & Cifarelli, C. P. (2025) · Scientific Reports · doi:10.1038/s41598-025-91331-2 · Cited by 12
German-Cortés, J., Herrero, R., Torroglosa, N., Pumarola, A., Fischer-Albiol, N., Campos-Moreno, S., Sabaté, S., Alcina, A. G., Mancilla, S., García-Lareu, B., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113616 · Cited by 11
Repurposing Clemastine to Target Glioblastoma Cell Stemness
Sun, M. A., Yang, R. R., Liu, H., Wang, W., Song, X., Hu, B., Reynolds, N., Roso, K., Chen, L. H., Greer, P. K., et al. (2023) · Cancers · doi:10.3390/cancers15184619 · Cited by 9
Self-citationModified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA Methyltransferases
Proto, M., Fiore, D., Piscopo, C., Laezza, C., Bifulco, M., & Gazzerro, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.815646 · Cited by 9
“Despite the efforts to identify new efficacious antitumor agents that are able to cross the blood–brain barrier, to date, temozolomide (TMZ) remains the most used drug in GBM treatment, but unfortunately, the onset of chemoresistance results in treatment failure and tumor recurrence (Stupp et al., 2005; Goenka et al.,…”
BackgroundShi, Z., Wu, Y., Zhuo, Q., Zuo, Y., Lin, J., Shi, H., Zhou, H., & Xu, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-34909-y · Cited by 10
Hu, Y., Zhou, L., Wang, Z., Ye, Z., Liu, H., Lü, Y., Qi, Z., Yang, K., Zeng, J., Li, H., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202401383 · Cited by 9
Subtirelu, R. C., Teichner, E. M., Ashok, A. B., Parikh, C., Talasila, S., Matache, I., Alnemri, A. G., Anderson, V. A., Shahid, O., Mannam, S., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1271822 · Cited by 9
“The existence of regulatory T cells (Tregs), myeloid-derived suppressor cells, and molecules such as PD-L1 could potentially debilitate dendritic cell activity and antigen presentation (89).”
BackgroundInfluentialCurrent trends in reoperation for recurrent glioblastoma: a meta-analysis (2007–2023)
Pichardo‐Rojas, P. S., Garcia-Torrico, F., Espinosa-Cantú, C. B., Elvir, F., la Fuente, A. C. B.-D., Hernandez-Garcia, M. S., Trippett, J. S., Morell, A. A., Shah, A. H., Komotar, R. J., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05058-1 · Cited by 7
“As shown in our HR analyses, many studies have reported only OS rather than PRS, which remains a significant limitation in the current literature [4].”
Zhang, C., Tan, L., Zheng, K., Xu, Y., Wan, J., Wu, J., Wang, C., Pin, G., & Feng, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1699134 · Cited by 8
Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2′-deoxyuridine (EdU)
Kaanoglu, H., Akyel, Y. K., Adefolaju, A., Valdivia, A., Higgins, D. M. O., Sellers, R. S., Mosely, C., Haswell, C. J., Zamboni, W. C., Hingtgen, S., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2532187123 · Cited by 7
“Currently, the standard of care for GBM consists of surgery followed by ionizing radiation and temozolomide (TMZ) drug therapy (5 –7).”
GBM Immunotherapy: Macrophage Impacts
Loginova, N., Aniskin, D., Timashev, P. S., Ulasov, I. V., & Kharwar, R. K. (2024) · Immunological Investigations · doi:10.1080/08820139.2024.2337022 · Cited by 7
“In addition, these signalling pathways are activated by changes in the microenvironment, e.g., artificial therapy, metabolism and mRNA splicing (Fedele et al., 2019; Goenka et al., 2021).”
Novak, M., Majc, B., Malavolta, M., Porčnik, A., Mlakar, J., Hren, M., Habič, A., Mlinar, M., Jovčevska, I., Šamec, N., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf015 · Cited by 9
Song, M., Xu, J., Gui, Z., Wu, Y., Wang, F., Sheng, H., Huang, X., Qian, J., Qin, H., & Wang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1573694 · Cited by 7
“The poor prognosis of GBM is largely attributed to its extensive inter-and intra-tumoral heterogeneity, acquired resistance to temozolomide (TMZ), and an immunosuppressive tumor microenvironment (Goenka et al., 2021; Tan et al., 2020).”
Ye, L., Cheng, Y., Li, P., Wang, Y., & Ma, W. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf037 · Cited by 7
“Our findings suggest that UDIPs, especially T1-34 and T1-96, hold promise as imaging biomarkers for differentiating primary from recurrent GBM, thereby strengthening existing diagnostic criteria [43].”
Saikosaponin D improves chemosensitivity of glioblastoma by reducing the its stemness maintenance
Liang, J. H., Sun, J. P., Liu, A., Chen, L., Ma, X., Liu, X., & Zhang, C. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101342 · Cited by 7
“Despite ongoing research, there has not been improvement in survival in glioblastoma, especially the chemoresistance of TMZ is the main challenge in the treatment of GBM [5].”
BackgroundApoE Inhibits the Progression of Glioma by Activating Immune Function
Liu, X., Chang, Y., Long, M., Huang, K., Wang, B., Gong, D., Luo, J., & Feng, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70697 · Cited by 6
Han, X., Feng, F., Wang, Z., Huang, S., Xi, K., Fang, Z., Shen, J., Wang, M., Zhang, Y., Liu, B., et al. (2025) · Advanced Materials · doi:10.1002/adma.202511351 · Cited by 6
Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026
Poe, J., Kim, C. J. H., Coleman, C., Nguyen, H. H. M., Velazhahan, V., Bergsneider, B. H.-L., Sanker, V., Kim, S., Chen, Y. M., Abikenari, M. A., et al. (2026) · Cells · doi:10.3390/cells15060561 · Cited by 9
“…to the suboptimal therapeutic responses include a profoundly immunosuppressive tumor microenvironment (TME) [10], the presence of glioblastoma stem cells that evade immune recognition [11], and adaptive resistance mechanisms that undermines the efficacy of immune checkpoint inhibitors [4].”
The IL13α 2R paves the way for anti-glioma nanotherapy
Ulasov, I. V., Borovjagin, A. V., Laevskaya, A., Kamynina, М., Timashev, P. S., Cerchia, L., & Rozhkova, E. A. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.006 · Cited by 6
Nakase, K., Matsuda, R., Sasaki, S., & Nakagawa, I. (2024) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2023.0042 · Cited by 8
“Some studies have reported that MMR-deficient gliomas could be resistant to TMZ [17].”
BackgroundWang, M. X., Graner, A. N., Knowles, B., McRae, C., Fringuello, A. R., Pauček, P., Gavrilovic, M., Redwine, M., Hanson, C., Coughlan, C. M., et al. (2024) · Neurology International · doi:10.3390/neurolint16060103 · Cited by 6
Song, D., Fan, G., & Chang, M. (2024) · Cancers · doi:10.3390/cancers17010074 · Cited by 8
Emerging nanoplatforms towards microenvironment-responsive glioma therapy
Tripathy, N. S., Sahoo, L., Paikray, S. K., & Dilnawaz, F. (2025) · Medical Oncology · doi:10.1007/s12032-024-02596-y · Cited by 7
“The overall survival of patients has been increased after receiving the standard care of chemotherapy and radiation therapy, even so the recurrence is unavoidable because of treatment resistance and the ineffectiveness of therapies [8, 9].”
Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
Kaanoglu, H., Adefolaju, A., Fraley, C., Shobande, M., Dasari, R., Mann, B., Bell, N., Keir, S. T., Higgins, D. M. O., Kram, D. E., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1098 · Cited by 7
Dialogue among Lymphocytes and Microglia in Glioblastoma Microenvironment
Mormino, A., & Garofalo, S. (2022) · Cancers · doi:10.3390/cancers14112632 · Cited by 7
Wöllner, A., Paul, A., Arquilla, M., Cao, J., Lotsch, C., Jungwirth, G., Jassowicz, L., von Deimling, A., Unterberg, A. W., Krieg, S. M., et al. (2025) · Cells · doi:10.3390/cells14100701 · Cited by 6
“As a consequence, with disease progression, tumors can acquire an increased resistance against radiation and systemic treatment modalities, including temozolomide, which further limits the effective use for recurrent GBM [8,9].”
Intranasal Terpene Treatment for Glioblastoma: the Neuro-Oncological Potential of Perillyl Alcohol
Harbi, E., Yarar, E., Mason, C. E., Aschner, M., & Altundağ, A. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04505-9 · Cited by 5
Zhai, Q., Cui, J., Tan, Z., Wu, H., Yu, Y., & Sun, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1726329 · Cited by 6
Galicka, A., Szoka, Ł., Radziejewska, I., & Marcinkiewicz, C. (2023) · Cancers · doi:10.3390/cancers15194805 · Cited by 5
“The most commonly used treatment for recurrent GBM is another alkylating agent, Lomustine; however, like TMZ, it is only effective in patients with MGMT promoter methylation [8,9].”
BackgroundCucurbitacin E inhibits the proliferation of glioblastoma cells via FAK/AKT/GSK3β pathway
Chen, W., Liu, F., Lin, X., Li, L., Chen, W., Zhang, T., Liu, Y., Niu, L., Zhang, Y., & Hu, P. (2023) · Oncology Reports · doi:10.3892/or.2023.8658 · Cited by 5
Lv, P., Wang, Z., Si, X., Su, J., Yu, Z., Yu, H., Ji, G., & Song, W. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.09.053 · Cited by 5
Habibi, M. A., Rashidi, F., Gharedaghi, H., Tavani, S. F., Farzalizadeh, H., Eftekhar, M. S., Bahri, A., Mohammadzadeh, I., & Hajikarimloo, B. (2025) · Neurosurgical Review · doi:10.1007/s10143-025-03335-1 · Cited by 5
“However, currently, GBM continues to exhibit unfavorable outcomes in terms of prognosis, with no considerable improvement observed in the survival rate of GBM patients [18].”
Reburn, C., Gawthorpe, G., Perry, A., Wood, M. E., & Curnow, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122668 · Cited by 5
“Current glioma treatment mortality rates are high, with most patients experiencing post-treatment tumour recurrence with poor prognosis (average survival after repeated resections is around 18 months) [2,3].”
Luo, W., Quan, Q., Xu, Z., Lei, J.-J., & Peng, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26859 · Cited by 4
Knockdown of ATRX enhances radiosensitivity in glioblastoma
Zhao, Y., Chen, Y., Liu, R., Liu, M., You, N., Zhao, K., Zhang, J., & Xu, B. (2024) · Chinese Neurosurgical Journal · doi:10.1186/s41016-024-00371-6 · Cited by 4
Yang, B., Han, Y., Shi, M., Lu, K., Wang, Y., Gao, Z., Zhang, Y., Qu, M., Chen, Z., Waye, M. M. Y., et al. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100039 · Cited by 4
Xu, K., Zhang, C., Weigao, Shi, Y., Pu, S., Huang, N., & Dou, W. (2025) · Gene · doi:10.1016/j.gene.2025.149214 · Cited by 4
Metadata
- Authors
- Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y.
- Affiliations
- Northwestern University (US)
- Corresponding author
- Cheng, Shi-Yuan
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-02-24
- Volume
- 10
- Issue
- 3
- Pages
- 484
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7995978
- OpenAlex
- W3132558808
- Cited by
- 169
- References
- 157
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 27 · 2023: 36 · 2022: 26 · 2021: 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (CA221747, CA234799)
- National Institute of Neurological Disorders and Stroke (NS093843, NS095634, NS115403)
- The Lou and Jean Malnati Brain Tumor Institute at Northwestern Medcine (10031379)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glioblastoma, treatment resistance, tumor recurrence, tumor heterogeneity, hypermutation, cancer metabolomics, alternative splicing, hypoxia, tumor microenvironment, immunosuppression, immunotherapy resistance, tumor evolution
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Neoplasm Recurrence, Local, Drug Resistance, Neoplasm, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.